Patients with primary dystonia, the third most prevalent movement disorder, suffer from a
markedly reduced quality of life. This might, at least in part, be mediated by non-motor symptoms…

Background Low-back pain is a common and costly problem. We estimated the effectiveness
of a group cognitive behavioural intervention in addition to best practice advice in people …

S/GSK1349572 is a next-generation HIV integrase (IN) inhibitor designed to deliver potent
antiviral activity with a low-milligram once-daily dose requiring no pharmacokinetic (PK) …

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity
against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance …

Three-hundred-and-thirteen back pain sufferers completed a screening questionnaire for
inflammatory back pain. This was positive in 46 (15%), who were invited for a further …

Integrase (IN) strand transfer inhibitors (INSTIs) have been developed to inhibit the ability of
HIV-1 integrase to irreversibly link the reverse-transcribed viral DNA to the host genome. …

… Underwood [1990] described and presented the results of the entire set of simulations
conducted for this study. Simulations xvere run to a "steady state" condition when changes in …

Background Chronic musculoskeletal pain is a common problem that is difficult to treat. Self-management
support interventions may help people to manage this condition better; …

… Initial studies suggest that 175X acts as an inhibitor of viral DNA processing in a manner
similar to that of BDCRB (MR Underwood, JC Drach, and KK Biron, unpublished results). …

2-Bromo-5,6-dichloro-1-β-d-ribofuranosyl benzimidazole (BDCRB) is a member of a new
class of benzimidazole ribonucleosides which inhibit human cytomegalovirus (HCMV) late in …